Claims for Patent: 6,572,856

Summary for Patent: 6,572,856

Title:	Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
Abstract:	The present invention relates to the treatment and prevention of cancer, viral infections and microbial infections by the administration of anti-C3b(i) antibodies. The present invention also relates to methods of treating and preventing cancer, viral infection, or microbial infection in an animal comprising administering to said animal IgG antibodies, IgM antibodies and/or complement components in combination with antibodies specific for C3b(i). The present invention also relates methods of treating and preventing cancer, viral infection or microbial infection in an animal comprising administrating said animal antibodies that immunospecifically bind to one or more cancer cell antigens, viral antigens or microbial antigens, respectively, in combination with antibodies immunospecific for C3b(i). The present invention further relates to the detection, imaging, diagnosis and monitoring of cancer utilizing C3b(i) specific antibodies.
Inventor(s):	Taylor; Ronald (Charlottesville, VA), Nardin; Alessandra (Paris, FR), Sutherland; William M. (Earlysville, VA), Sokoloff; Mitchell H. (Hinsdale, IL), Chung; Leland (Lovingston, VA)
Assignee:	The University of Virginia Patent Foundation (Charlottesville, VA)
Application Number:	09/724,620
Patent Claims:	1. A method for treating or preventing cancer in an animal, said method comprising administering to the animal a therapeutically or prophylactically effective amount of one or more anti-C3b(i) antibodies. 2. A method for treating or preventing cancer in an animal, said method comprising administering to the animal a therapeutically or prophylactically effective amount of one or more anti-C3b(i) antibodies and one or more antibodies immunospecific for a cancer cell antigen. 3. The method of claim 1 or 2, wherein at least one of the anti-C3b(i) antibodies is immunospecific specific for C3b(i) linked to IgM or IgG bound to cancer cells. 4. The method of claim 1 or 2, wherein at least one of the anti-C3b(i) antibodies is immunospecific for C3b(i) linked to proteins or lipids on cancer cells. 5. The method of claim 1 or 2, wherein at least one of the anti-C3b(i) antibodies is a bispecific antibody which is immunospecific for C3b(i) and an effector cell receptor or antigen. 6. The method of claim 5 in which the effector cell is a lymphocyte, monocyte, macrophage, dendritic cell, neutrophil, natural killer cell, or erythrocyte. 7. The method of claim 6 in which the effector cell is an erythrocyte. 8. The method of claim 5 in which the receptor or antigen is CR1, CR2, CR3, CR4, CD16, CD32, CD64, or CD89. 9. The method of claim 1 or 2, wherein at least one of the anti-C3b(i) antibodies is a monoclonal antibody. 10. The method of claim 9 in which the monoclonal antibody is a human or humanized monoclonal antibody. 11. The method of claim 1 or 2 further comprising administering to the animal IgG enriched plasma. 12. The method of claim 1 or 2 further comprising administering to the animal IgM enriched plasma. 13. The method claim 1 or 2 further comprising administering to the animal one or more complement components. 14. The method of claim 2 in which at least one of the anti-C3b(i) antibodies is conjugated to a therapeutic agent. 15. The method of claim 11 further comprising administering to the animal one or more complement components. 16. The method of claim 12 further comprising administering to the animal one or more complement components. 17. The method of claim 11 further comprising administering IgM enriched plasma and one or more complement components. 18. The method of claim 2 in which at least one of the anti-C3b(i) antibodies is conjugated to a detectable agent. 19. The method of claim 1 or 2 further comprising administering to the animal plasma. 20. The method of claim 1 or 2 in which the animal is a mammal. 21. The method of claim 1 or 2 in which the animal is a human. 22. A method of treating cancer in an animal, said method comprising administering to said animal a therapeutically effective amount of an antibody immunospecific for C3b(i) covalently linked to IgM or IgG bound to cancer cells. 23. A method of treating cancer in an animal, said method comprising administering to said animal a therapeutically effective amount of an antibody immunospecific for C3b(i) covalently linked to proteins or lipids on cancer cells. 24. A method of treating cancer in an animal, said method comprising administering to said animal a therapeutically effective amount of an anti-C3b(i) antibody and an anti-CD20 antibody. 25. The method of claim 2, wherein the cancer cell antigen is CD20, HER2 or PSMA. 26. The method of claim 24, wherein the anti-C3b(i) antibody is a bispecific antibody which is immunospecific for C3b(i) and an effector cell receptor or antigen. 27. The method of claim 26 in which the effector cell is a lymphocyte, monocyte, macrophage, dendritic cell, neutrophil, natural killer cell, or erythrocyte. 28. The method of claim 27 in which the effector cell is an erythrocyte. 29. The method of claim 26 in which the antigen is CR1, CR2, CR3, CR4, CD16, CD32, CD64, or CD89. 30. The method of claim 22, 23 or 24, wherein the anti-C3b(i) antibody is a monoclonal antibody. 31. The method of claim 30 which the monoclonal antibody is a human or humanized monoclonal antibody. 32. The method of claim 22 or 23 further comprising administering to the animal IgG or IgM enriched plasma. 33. The method claim 22 or 23 further comprising administering to the animal one or more complement components. 34. The method of claim 22, 23 or 24 in which the anti-C3b(i) antibody is conjugated to a therapeutic agent. 35. The method of claim 32 further comprising administering to the animal one or more complement components. 36. The method of claim 22 or 23 further comprising administering to the animal plasma. 37. The method of claim 22, 23 or 24 in which the animal is a mammal. 38. The method of claim 37 in which the mammal is a human. 39. The method of claim 2, wherein at least one of the anti-C3b(i) antibodies is 3E7 produced by the hybridoma deposited with the ATCC as Accession No. PTA-4090. 40. The method of claim 22, 23 or 24, wherein the anti-C3b(i) antibody is 3E7 produced by the hybridoma deposited with the ATCC as Accession No. PTA-4090. 41. The method of claim 24, wherein the anti-CD20 antibody is rituximab. 42. The method of claim 24, wherein the anti-C3b(i) antibody is 3E7 produced by the hybridoma deposited with the ATCC as Accession No. PTA-4090 and the anti-CD20 antibody is rituximab. 43. The method of claim 24, wherein the anti-C3b(i) antibody is immunospecific for C3b(i) covalently linked to IgM or IgG bound to cancer cells. 44. The method of claim 24, wherein the anti-C3b(i) antibody is immunospecific for C3b(i) covalently linked to proteins or lipids in cancer cells. 45. The method of claim 22 or 23, further comprising administering to the animal one or more purified complement components. 46. The method of claim 22 or 23, further comprising administering plasma to the animal.

Details for Patent 6,572,856

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2018-09-10
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2018-09-10
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2018-09-10